{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T06:48:57Z","timestamp":1785653337192,"version":"3.56.0"},"reference-count":148,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Arlene Witmer Memorial Fund for Bone Marrow Cancer Research"},{"name":"John and Denise Gilliland Fund for the Cancer Genetics Program"},{"name":"G. R. Sponaugle Employee Cancer Research Fund"},{"name":"Earl \u201cBumps\u201d Clouser Memorial Lymphoma Research Endowment, Megan and Andrew Enders Stewardship"},{"name":"Richard E. and Stephanie A. Ziegler Charitable Foundation Endowment in Hematology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>In recent years, treatments in the field of hematologic malignancies have undergone significant evolution; allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shifted from an \u201cultimate\u201d therapy to becoming a component of a comprehensive therapeutic strategy for acute myeloid leukemia (AML). Advances in risk stratification (including molecular profiling and measurable residual disease assessment), conditioning regimens, and graft-versus-host disease (GVHD) prophylaxis\u2014such as post-transplant cyclophosphamide\u2014have improved outcomes and expanded donor selection and transplant eligibility. We should not only focus on the transplantation procedure but also consider various therapeutic components, including chemotherapy, targeted therapy (possibly including chimeric antigen receptor T-cell therapy), and post-transplant maintenance therapy, which need to be orchestrated within the broader context of leukemia treatment. In this review, we summarized key developments in allo-HSCT for AML and aim to \u201cdecipher\u201d each component of transplantation.<\/jats:p>","DOI":"10.3390\/cells14080572","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:26:41Z","timestamp":1744284401000},"page":"572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-7356","authenticated-orcid":false,"given":"Yoshitaka","family":"Inoue","sequence":"first","affiliation":[{"name":"Blood and Marrow Transplant Program, Division of Hematology and Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA"},{"name":"Cancer Institute, Penn State College of Medicine, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Cioccio","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Division of Hematology and Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-7080","authenticated-orcid":false,"given":"Shin","family":"Mineishi","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Division of Hematology and Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Minagawa","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Division of Hematology and Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"ref_1","unstructured":"(2025, February 13). Available online: https:\/\/cibmtr.org\/CIBMTR\/Resources\/Center-Specific-Survival-Analysis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2022-163044","article-title":"Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group","volume":"140","author":"Fenwarth","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2022009100","article-title":"Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"Jama"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","article-title":"Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial","volume":"9","author":"Schliemann","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1182\/blood.2023023476","article-title":"Management of adult patients with CMML undergoing allo-HCT: Recommendations from the EBMT PH&G Committee","volume":"143","author":"Onida","year":"2024","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: A European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood-2014-06-577023","article-title":"Phase 3 clinical trial of steroids\/mycophenolate mofetil vs steroids\/placebo as therapy for acute GVHD: BMT CTN 0802","volume":"124","author":"Logan","year":"2014","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood-2010-05-285502","article-title":"A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission","volume":"117","author":"Kurosawa","year":"2011","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: Results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","volume":"388","author":"Hamadani","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of Minimal Residual Disease in Standard-Risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular Minimal Residual Disease in Acute Myeloid Leukemia","volume":"378","author":"Grob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bono, R., Sapienza, G., Tringali, S., Rotolo, C., Patti, C., Mule, A., Calafiore, V., Santoro, A., and Castagna, L. (2024). Allogeneic Stem Cell Transplantation in Refractory Acute Myeloid Leukaemia. Cells, 13.","DOI":"10.3390\/cells13090755"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41375-023-02119-0","article-title":"Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission","volume":"38","author":"Yanada","year":"2024","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/bloodadvances.2024013214","article-title":"Measurable residual disease as predictor of post-day +100 relapses after allografting in adult AML","volume":"9","author":"Ali","year":"2025","journal-title":"Blood Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41375-023-02084-8","article-title":"Perspective on measurable residual disease testing in acute myeloid leukemia","volume":"38","author":"Walter","year":"2024","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-024-02378-5","article-title":"Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)","volume":"38","author":"Othus","year":"2024","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.3324\/haematol.2022.280747","article-title":"Delving the depths of measurable residual disease negativity in acute myeloid leukemia","volume":"107","author":"Freeman","year":"2022","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Naik, S., Rakszawski, K., Zheng, H., Claxton, D., Minagawa, K., and Mineishi, S. (2024). Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25020957"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"37","author":"Badar","year":"2023","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sallman, D.A., and Stahl, M. (2024). TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?. Blood, in press.","DOI":"10.1182\/blood.2024024245"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/hematology.2022000354","article-title":"Transplant for TP53-mutated MDS and AML: Because we can or because we should?","volume":"2022","author":"Versluis","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","article-title":"Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML","volume":"8","author":"Nawas","year":"2024","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/cncr.34268","article-title":"Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia","volume":"128","author":"Loke","year":"2022","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood.2021014520","article-title":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML","volume":"139","author":"Murdock","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.jtct.2023.03.008","article-title":"TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia","volume":"29","author":"Mason","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2021-154151","article-title":"Non-Relapse Mortality in TP53-Mutated MDS\/AML\u2014A Multi-Center Collaborative Study","volume":"138","author":"Byrne","year":"2021","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2019-131530","article-title":"Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation","volume":"134","author":"Chan","year":"2019","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for","volume":"40","author":"Mishra","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","article-title":"Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbmt.2014.10.025","article-title":"Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy","volume":"21","author":"Othus","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/leu.2011.13","article-title":"Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia","volume":"25","author":"Craddock","year":"2011","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/bmt.2017.61","article-title":"Allogeneic transplantation in primary refractory AML","volume":"52","author":"Ferguson","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1182\/blood-2011-06-358010","article-title":"Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies","volume":"118","author":"Magenau","year":"2011","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bmt.2016.188","article-title":"A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation","volume":"52","author":"Magenau","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.leu.2404143","article-title":"Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia","volume":"20","author":"Platzbecker","year":"2006","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): A randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/bmt.2010.32","article-title":"Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML","volume":"45","author":"Locke","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/blood.V120.21.4511.4511","article-title":"Early Experience with Clofarabine Pre-Conditioning Prior to Full Intensity or Reduced Toxicity Allogeneic Stem Cell Transplantation: A Promising New Therapy for the Treatment of Refractory Acute Leukaemia","volume":"120","author":"Richardson","year":"2012","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12185-018-2431-5","article-title":"Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML","volume":"108","author":"Rakszawski","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.hemonc.2021.03.001","article-title":"Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia","volume":"16","author":"Keruakous","year":"2023","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial","volume":"38","author":"Gao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/s41409-019-0677-z","article-title":"Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia","volume":"55","author":"Ma","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101109","DOI":"10.1016\/j.beha.2019.101109","article-title":"Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"32","author":"Appelbaum","year":"2019","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as Post-Transplant Maintenance for AML with Internal Tandem Duplication Mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet Lond. Engl."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.13977","article-title":"Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation","volume":"173","author":"Mehta","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: An open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ajh.24959","article-title":"Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant","volume":"93","author":"Sandmaier","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2024-207763","article-title":"Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML","volume":"144","author":"Oran","year":"2024","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","article-title":"Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia","volume":"29","author":"Fathi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1182\/blood-2022-169964","article-title":"Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations","volume":"140","author":"Salhotra","year":"2022","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"58","author":"Kent","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1111\/cas.15048","article-title":"Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"112","author":"Wei","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","article-title":"Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML","volume":"8","author":"Garcia","year":"2024","journal-title":"Blood Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes","volume":"24","author":"Oran","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_89","first-page":"1254","article-title":"Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission","volume":"96","author":"Tallman","year":"2000","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/cncr.28498","article-title":"Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"120","author":"Yeshurun","year":"2014","journal-title":"Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MOH.0000000000000410","article-title":"When should patients receive consolidation chemotherapy before allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission?","volume":"25","author":"Yeshurun","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.beha.2016.10.012","article-title":"Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission","volume":"29","author":"Appelbaum","year":"2016","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ajh.24834","article-title":"History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission","volume":"92","author":"Rashidi","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.7326\/0003-4819-129-12-199812150-00007","article-title":"Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease","volume":"129","author":"Brodsky","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bbmt.2014.08.014","article-title":"Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease","volume":"21","author":"Roy","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1182\/bloodadvances.2019000134","article-title":"PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade","volume":"3","author":"Ikegawa","year":"2019","journal-title":"Blood Adv."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Mancusi, A., Piccinelli, S., Velardi, A., and Pierini, A. (2019). CD4+FOXP3+ Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02901"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/S2666-6367(21)00301-8","article-title":"Post-Transplant Cyclophosphamide As GVHD Prophylaxis Eliminates GVHD Mortality and Improves Overall Survival in Alternative Donor Allogeneic Stem Cell Transplant","volume":"27","author":"Cioccio","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"E396","DOI":"10.1002\/ajh.26296","article-title":"Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation","volume":"96","author":"Jamy","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtct.2023.12.021","article-title":"Interim Results of a Phase I\/II Trial of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Mismatched Bone Marrow Transplantation for Older or Unfit Patients","volume":"30","author":"McCurdy","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e12629","DOI":"10.1111\/tid.12629","article-title":"Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation","volume":"19","author":"Slade","year":"2017","journal-title":"Transpl. Infect. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41409-020-01092-x","article-title":"Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: Impact of HLA donor matching","volume":"56","author":"Irene","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41409-019-0475-7","article-title":"Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: A study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)","volume":"54","author":"Fayard","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2014-11-608539","article-title":"Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation","volume":"125","author":"Cieri","year":"2015","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"107530","DOI":"10.1016\/j.leukres.2024.107530","article-title":"Impact of post-transplant cyclophosphamide and splenomegaly on primary graft failure and multi-lineage cytopenia after allogeneic hematopoietic cell transplantation","volume":"143","author":"Zulch","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"106969","DOI":"10.1016\/j.leukres.2022.106969","article-title":"Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity\/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide","volume":"123","author":"Shah","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.27597","article-title":"Update in GVHD Prophylaxis: Novel Pharmacologic and Graft Manipulation Strategies","volume":"100","author":"Hexner","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors","volume":"13","author":"Brissot","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41409-024-02284-5","article-title":"Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"59","author":"Nagler","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"20406207231152644","DOI":"10.1177\/20406207231152644","article-title":"Role of abatacept in the prevention of graft-versus-host disease: Current perspectives","volume":"14","author":"Ngwube","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.2023023660","article-title":"Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation","volume":"144","author":"Kean","year":"2024","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-142974","article-title":"Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants","volume":"136","author":"Meyer","year":"2020","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood-2021-154191","article-title":"Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study","volume":"138","author":"Hoeg","year":"2021","journal-title":"Blood"},{"key":"ref_120","first-page":"S108","article-title":"Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients","volume":"31","author":"Meyer","year":"2025","journal-title":"Transplant. Cell. Ther. Off. Publ. Am. Soc. Transplant. Cell. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"S317","DOI":"10.1016\/S2152-2650(24)01207-2","article-title":"AML-521 Treatment of Acute Myeloid Leukemia With Orca-T","volume":"24","author":"Srour","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood-2024-204256","article-title":"Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies","volume":"144","author":"Abedi","year":"2024","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbmt.2015.10.019","article-title":"Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/bloodadvances.2021004829","article-title":"Better the cure you know: Why patients with AML \u2265 60 years of age should be offered early allogeneic stem cell transplantation","volume":"6","author":"Tey","year":"2022","journal-title":"Blood Adv."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","article-title":"Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): An alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study","volume":"33","author":"Ustun","year":"2019","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2019.05.037","article-title":"Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age > 69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"Ringden","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"172.e1","DOI":"10.1016\/j.jtct.2024.12.022","article-title":"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older: A Systematic Review and Meta-Analysis","volume":"31","author":"Shahzad","year":"2025","journal-title":"Transplant. Cell Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/bloodadvances.2020001719","article-title":"Geriatric assessment in older alloHCT recipients: Association of functional and cognitive impairment with outcomes","volume":"4","author":"Olin","year":"2020","journal-title":"Blood Adv."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2023-173855","article-title":"The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704","volume":"142","author":"Artz","year":"2023","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet. Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: Evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: Evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-04-713644","article-title":"Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia","volume":"128","author":"Elmaagacli","year":"2016","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Morishita, T., Martin, P.J., and Inamoto, Y. (2025). Treatment Response in Individual Organs Affected by Chronic Graft-Versus-Host Disease. Cells, 14.","DOI":"10.3390\/cells14040238"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.27594","article-title":"Prediction and Prognostication of Acute Graft-Versus-Host Disease by MAGIC Biomarkers","volume":"100","author":"Levine","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: The ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: A refined classification from the European society for blood and marrow transplantation (EBMT)","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.bbmt.2018.05.025","article-title":"Novel Ultrasonographic Scoring System of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation","volume":"24","author":"Nishida","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15267","article-title":"Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"181","author":"Kernan","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S2352-3026(23)00011-X","article-title":"Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): A randomised, multicentre, phase 3 trial","volume":"10","author":"Grupp","year":"2023","journal-title":"Lancet Haematol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/8\/572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:12:29Z","timestamp":1760029949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/8\/572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":148,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cells14080572"],"URL":"https:\/\/doi.org\/10.3390\/cells14080572","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}